Abstract
INTRODUCTION
Approximately 170 million people worldwide are chroni cally infected with hepatitis C virus (HCV) [1] . Until recently, the most effective treatment against HCV infection was the combination of pegylated interferonα 2a or b and ribavirin (PR) which achieved sustained virological response (SVR) in about 45% of individuals infected by HCV genotype 1, 65% by HCV genotype 4, 70% by HCV genotype 3 and more than 85% by HCV genotype 2 [2, 3] . The frequent side effects associated with PR and the rates of non response to PR includes partial or null virologic response and breakthrough or relapse after PR discontinuation. Thus, development of novel and more effective antiviral treatments were essential [4] . Two HCV NS3 protease inhibitors (PI), boceprevir (BOC) and telaprevir (TVR) have been approved and combined with PR, have increased the SVR to about 75% in therapy naïve HCV genotype 1 infected patients [59] .
Over the past few years, other direct acting antivirals (DAAs) were developed [1014] as second generation of PI with higher antiviral potency, HCV NS5A replication complex inhibitors and nucleotide analogue HCV NS5B polymerase inhibitors [13] as well as hosttargeted indirect antivirals like cyclophilin inhibitors [15] and lambda interferon [15] . In terferonfree treatments with new DAAs are expected to cure more than 90% of HCVinfected patients [16] . But they are not available in all the countries [17] . At the present time, triple therapy combining PR with NS3 PI (TVR or BOC) is going to remain the main treatment for HCV patients [1621] . That is why it appears important to continue research in limiting virus replication and the autophagy inhibition could be a new additional pathway because of recent evidences obtained regarding to an increased autophagic response in the liver of chronically HCV infected patients [22] . Autophagy is a catabolic process which degrades a cellular own component through the lysosomal machi nery [23] . It has been shown that autophagy is activated during virus and bacterial infection [24] and that some viruses can use the autophagy system to facilitate their own replication [2529] . Previously, several studies evidenced that HCV infection resulted in endoplasmic reticulum stress and autophagy responses, that HCV regulated the autophagy pathway, that the autophagy machinery was required to initiate HCV replication, and finally, that the suppression of autophagy inhibited HCV replication [3035] . Interestingly, it has been demonstrated that HCV induces autophagosomes via a Class Ⅲ PI3Kindependent path way and uses autophagosomal membranes as sites for its RNA replication [36] . The lysosomotropic antimalarial drugs, chloroquine (CQ) and hydroxychloroquine (HCQ), belonging to the quinoline family, are among the autophagy inhibitors, which act by preventing the acidification of lysosomes, leading to the inhibition of both fusion of autophagosome with lysosome and lysosomal protein degradation [23] . In fact, CQ exerts an inhibitory effect for several RNA viruses including coronaviruses, flaviviruses and human immunodeficiency virus [3739] . Recently, it has been shown that a treatment with CQ of HCV infected cells suppressed the replication of the virus in a dosedependent manner by preventing the autophagic proteolysis [40] .
In the present study, we used the established ex vivo model of primary human liver slices culture which allows to the de novo replication of primary viral isolates and production of high titer infectious HCV particles [41] to evaluate the potential antiviral potency GNS396 [42] , a new autophagy inhibitor in comparison with a well known autophagy inhibitor, HCQ. Presented results might be additional options to treat HCV infected individuals.
MATERIALS AND METHODS

Human liver tissue specimens
Adult human primary liver tissue samples were obtained from HCV and also hepatitis B virus, and human immuno deficiency virus seronegative patients who underwent liver resection surgery, mainly for liver metastasis in the absence of underlying liver disease. Experimental procedures were carried out in accordance with French laws and Regulations.
Liver slices preparation, culture and infection
Slices were prepared and cultured as described [41, 43] . Briefly, uninfected human liver slices, obtained from human liver resection, were cut into 350 µm thick slices of (2.7 × 10 6 cells per slice) with a vibratome (Leica, VTS1200) and transferred to 0.4 µm organotypic cul ture inserts (Millipore) in 12wells plates (1 slice/well) containing 2 mL of complete Dulbecco's modified eagles's medium (DMEM) culture media and maintained at 37 ℃ under a constant flow of humidified 95% O2/5% CO2 for up to 24 h before viral infection. Cell number for tissue slices was estimated at approximately 2.7 × 10 6 cells per slice based on a 14cell thick slice (cell diameter approximately 25 µm) [41] . The complete culture medium consisted of DMEM with 4.5 g/L Dglucose and glutamine (Life Technologies) supplemented with 10% fetal calf serum (Life Technologies, 16000044), 5% penicillin streptomycin (Life Technologies, 10378016), 1% amphotericin (Sigma Aldrich), 5 µg/mL insulin (Life Technologies, 51500056), 0.4 µg/mL dexametha sone (Sigma Aldrich, D4902), 10 mmol/L HEPES (Life Technologies, 15630080), nonessential amino acids (Life Technologies), 20 mmol/Lsodium pyruvate (Life Technologies) and 50 µg/mL ascorbic acid (Sigma Aldrich). One day postculture in twelvetranswell plates, human primary liver slices were inoculated with HCV Con1/C3 at a multiplicity of infection equal to 0.1 at 37 ℃ in the same culture conditions as described above, for overnight. The infectious clone Con1/C3 (genotype 1b) (JFH1derived chimeric viruses whose structural proteins are encoded by the genotype 1bHCV sequence Con1) [44] could efficiently infect human liver slices which main tain their hepatocyte differentiation and retain normal physiological and biochemical parameters for at least 10 d. The inoculum was then removed; the slices were washed three times with PBS and then supplemented with complete culture medium. Then, liver slices were cultured without medium replacements, as previously described [41] .
HCV RNA transfection and virus production
To produce HCVcc, viral RNAs were transcribed in vitro and electroporated into Huh7.5.1 cell line (kindly provided by Professor Francis V Chisari, The Scripps Research Institute, La Jolla, CA), as described previously [45] . The infectious titer of cell culture supernatants was evaluated by classical titration assay [45] . In brief, the HCV infection of Huh7.5.1 cells was performed with serial 10fold dilu tion of viral supernatants. Seventytwo hours later, the formation of infected cells foci were detected by staining with human HCV positive sera or mouse monoclonal antibodies directed against HCV core (Ozyme) and nons tructural (NS5A) (Virostat, clone1877) proteins. Titrations were performed in duplicate.
Quantification of HCV strands RNA by real-time quantitative reverse transcription-polymerase chain reaction
A strandspecific realtime quantitative reverse trans criptionpolymerase chain reaction technique to quantify the intracellular levels of positive and negative strand HCV RNA was performed as previously described [4649] . The quantification of 28S rRNA was used as an internal standard to quantify HCV in total liver RNA, as pre viously described [46] , (threshold of detection: 25 copies/ reaction). Briefly, reverse transcription was carried out using oligo(dT) primer (Life Technologies) and Moloney murine leukemia virus reverse transcriptase (Promega) as recommended by the manufacturer. Realtime polymerase chain reactions were performed using the Light CyclerR (Roche Applied Science) and Fast Start DNA Master SYBR Green Ⅰ kit (Life Science, Roche) according with the manufacturer's protocol.
Reverse transcription was performed using primers located in the 5' NCR region of HCV genome, tagRC1 (5'GGC CGT CAT GGT GGC GAA TAA GTC TAG CCA TGG CGT TAG TA3') [47] and RC21 (5'CTC CCG GGG CAC TCG CAA GC3') [48] for the negative and positive strands, respectively, as described previously [46] . After a denaturation step performed at 70 ℃ for 8 min, the RNA template was incubated at 48 ℃ for 5 min in the presence and RC21 primers for positivestrand amplification, or tag (5'GGC CGT CAT GGTGGC GAA TAA3') and RC21 primers for negative strand amplification. The PCR pro tocol consisted of 18 cycles of denaturation (94 ℃ for 1 min), annealing (55 ℃ for 45 s), and extension (72 ℃ for 2 min). The cDNA obtained was purified using the Quickclean kit (Qiagen), according to the manufacturer's instructions, and 2 µL of the purified product suspended in 10 µL nuclease free water (Promega) were then subjected to realtime PCR. The reaction was carried out using the DNA Fast Start SYBR Green Kit (Life Science, Roche), with LightcyclerTM instruments and technology (Roche Diagnostics). PCR amplifications were performed in a total volume of 20 µL, containing 3 mmol/L MgCl2, 2 µL DNA Master green (Life Science) and 50 ng of the 197 R (5'CTTTCGCGACCCAACACTAC3') and 104 (5'AGAGCCATAGTGGTCTGCGG3') primers [48, 49] . The PCR protocol consisted of one step of initial denaturation for 10 min at 94 ℃, followed by 40 cycles of denaturation (95 ℃ for 15 s), annealing (57 ℃ for 5 s), and extension (72 ℃ for 8 s). After amplification, the specificity of PCR products was checking by a melting curve analysis.
Western blotting
Western blotting was performed as following. Each liver slice was washed 3 times in PBS, incubated in Laemmli buffer [50] at 100 ℃ for 10 min. The lysate was passed through a 26 G needle, 10 times and kept at 80 ℃.
Before electrophoresis in precast sodium dodecyl sul fate polyacrylamide gel 4%12% (Life Technologies), the samples were incubated at 95 ℃ for 5 min. After electrophoresis, proteins were transferred to a 0.22 µm Protran membrane BA83 (Schleicher and Schuell) and HCV proteins were detected by Western blotting using mouse monoclonal antibodies to core (C750, 1:10000) (Ozyme), to NS5A (1:2000) (Virostat, clone 1877), to LC3 proteins (SigmaAldrich) and to glyceraldehyde3 phosphate dehydrogenase (GAPDH) (Abcam), and to βactin (Pierce biotechnology). Horseradish peroxidase conjugated antimouse IgG (GeHealthCare Life Sciences) at the dilution of 1:50000 were used as secondary antibodies. The reactions were developed using enhanced chemiluminescence detection reagents (GeHealthCare Life Sciences), followed by exposure to XOMAT film (GeHealthCare Life Sciences). LC3Ⅱ protein expression analysis was performed with Image J software.
Drugs inhibition of HCVсс Сon1/C3 replication and cytotoxicity assays
The HCVcc Con1/C3 inhibition either by pegylatedinter feron α2a (pegINF) (Roche, Pegasys) or/and ribavirin (RBV) (Schering Plough, Rebetol) or TVR (Janssen Cilag, Incivo) or BOC (ScheringPlough, Boceprevir) or SOF (Gilead Sciences Intl Ltd, Sofosbuvir) or GNS396 ( Figure 1 ) (Genoscience Pharma, Marseille, France) or HCQ ( Figure 1 ) (Genoscience Pharma, Marseille, France) or 0.5% dimethylsufoxide (DMSO) (Sigma Aldrich) as a carrier control, and the cytotoxicity assays were performed as following. At day 4 postinfection with HCVcc Con1/ C3 the human liver slices were treated by addition of different concentrations of the following drugs: peg INF or/and RBV or TVR or BOC or SOF or HCQ (0.1, 1, 2.5, 5 µmol/L or a new quinoline derivative, GNS396 (0.1, 1, 2.5, 5 µmol/L) alone or 0.5% DMSO as a carrier control, to culture medium, twice daily, up to day 10 postinfection. The infectivity (ffu/mL) was measured at day 2, day 4 or day 6 posttreatment depending on the experiment as described [41] . All the experiments were performed in triplicate. The cytoTox 96R NonRadioac tive Cytotoxicity Assay (Promega, G1780) was used to assess the potential cytotoxicity of the drugs. Results of lactate deshydrogenase (LDH) leakage were compared to the carrier control calculated ( Figure 2 ) as described previously [51] .
Evaluation of autophagy modulation and inhibition
Autophagy modulation was evaluated on HeLa cells treated with GNS396, a new quinolone derivative. For tracking different stages of autophagy the tandem fusion of mRFP and EGFP fused to LC3 make a pHsensitive sensor (mRFPEGFPLC3) that is used to monitor auto phagy in live cells [52] . The EGFP tag is acidsensitive while the mRFP tag is not. The double tagged LC3 can be used to label autophagosomes, amphisomes and auto lysosomes. In autophagosomes, both tags emit yellow light. However, the fusion of autophagosomes to acidic lysosomes results in acidic autolysosomes where the green fluorescence from GFP is lost. Subsequently, the red fluorescence from mRFP is lost when the double tagged protein is degraded. The autophagic flux inhibition was shown using a SkBr3 mRFP1EGFPLC3 stable breast cancer cell line treated with 100 µmol/L GNS396 or 100 µmol/L HCQ during 6 h. HCQ was used as a positive control of autophagy inhibition. Cell images were obtained using an epifluorescence microscope (Nikon, Autophagy inhibition was evaluated on HeLa cells treated with GNS396, at different drug concentrations (1, 10, 100 µmol/L) during 4 h or 6 h in the presence or absence of bafilomycine A1 (100 nmol/L) (SigmaAldrich) added for the last 2 h. Bafilomycin A1 (BafA1) is an autophagy inhibitor as endosomal acidification inhibitor. It is a known inhibitor of the late phase of autophagy. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes. Bafilomycin A1 acts by inhibiting vacuolar H+ ATPase [53, 54] . HCQ was used as a positive control of autophagy inhibition. 
Statistical analysis
At different days of the kinetics, the results were obtained from the mean of the three slices culture. Statistical tests were performed using the GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, United States). Values are expressed as means ± standard errors of the mean. The data were compared using an unpaired twotailed student's ttest or the MannWhitney ranksum test. Pvalue < 0.05 was considered significant.
RESULTS
Validation of GNS-396, a new quinoline derivative, as inhibitor of autophagy
We evaluated the effect of GNS396 (Figure 1 ) [42] , a new quinoline derivative, on autophagy by treatment of HeLa cells with various concentrations of GNS396 during 6 h. HCQ was used as a positive control of autophagy inhibition. The microtubuleassociated protein 1A/1B light chain 3 (LC3) is a soluble ubiquitinlike protein with a molecular mass of approximately 17 kDa that exists ubiquitously in mammalian tissues and cultured cells, as an unconjugated form (LC3Ⅰ) or conjugated to autophagosomes membranes (LC3Ⅱ: lipidated form). During autophagy, a cytosolic form of LC3 (LC3Ⅰ) is conjugated to phosphatidylethanolamine to form LC3 phosphatidylethanolamine conjugate (LC3Ⅱ), which is recruited to autophagosomal membranes allowing for the closure of the autophagic vacuole. Autophagosomes fuse with lysosomes to form autolysosomes, and intra autophagosomal components are degraded by lysosomal hydrolases. At the same time, LC3Ⅱ in autolysosomal lumen is degraded. Thus, lysosomal turnover of the autophagosomal marker LC3Ⅱ reflects autophagic activity. Analysis of LC3 intracellular expression by Western blotting demonstrated an increase of normalized LC3Ⅱ protein expression when HeLa cells were treated with GNS396, in a dosedependent manner ( Figure 3A) , reflecting the accumulation of autophagosomes in cells, and therefore an effective modulation of the autophagy. Consequently, GNS396 is a dosedependent autophagy modulator with a magnitude of normalized LC3 Ⅱ similar to which achieved with HCQ treatment, a well known autophagic inhibitor ( Figure 3B ). Similar results were obtained on Huh7.5.1 cell line (data not shown).
To evaluate if the observed accumulation of autopha gosomes after GNS396 treatment was a consequence of either a stimulated production of new autophagosomes (in this case, GNS396 would be an autophagy inducer) or a result of autophagosome clearance blockage (in this case, GNS396 would be an autophagy inhibitor), HeLa cells were treated with different concentrations of GNS396 in the absence or presence of a lysosomal protease inhibitor, Bafilomycin A1, that increases lysosomal pH and blocks autophagosomelysosome fusion ( Figure 3C ) and LC3 protein levels were measured. HCQ was used as a positive control of autophagy inhibition ( Figure 3D the accumulation of LC3Ⅱ was observed ( Figure 3C ) which was not enhanced in the presence of BafA1, sup porting the idea that GNS396 inhibits autophagic flux as HCQ ( Figure 3D ). To confirm that GNS396 is an autophagy inhibitor, the autophagic flux was monitored by fluorescence microscopy, using the mRFPEGFPLC3 tandemtagged fluorescent protein in SkBr3 mRFPEGFP LC3 stable cell line (Figure 4) . In green/red merged images, yellow dots (i.e., mRFP+EGFP+) indicate autophagosomes or nonacidic autolysosomes, while red dots (i.e., mRFP+EGFP) indicate autolysosomes. The autophagy flux is increased when both yellow and red punctua (dots) are increased in cells while the autophagic flux is blocked when only yellow punctua (dots) are increased without an accompanying increase of red punctua in cells. SkBr3 mRFPEGFPLC3 stable cell line was treated during 6 h with either GNS396 ( Figure  4C ) or HCQ, a wellknown autophagic inhibitor ( Figure  4B ) (100 µmol/L). An accumulation of yellow punctua (dots) corresponding to autophagosomes or nonacidic autolysosomes was noticeable ( Figure 4B and C), indicating that GNS396 blocks the autophagic flux, and may act as lysosomotropic agent as HCQ.
Modulation of autophagy and inhibition of HCV infection in human liver slices model by GNS-396 treatment
The level of LC3 and viral proteins expression were analysed by Western blotting after 1, 4, 6 and 10 d post infection ( Figure 5 ). HCV infection induced autophagy with an increase of protein LC3Ⅱ expression ( Figure  5B ) as compared to noninfected liver slices ( Figure 5A ), along with an increase of intracellular expression of the core and NS5A proteins consistent with the previous reports [22, 36] . Intracellular expression of the viral proteins was decreased significantly at day 6 posttreatment with HCQ (1 µmol/L) or GNS396 (1 µmol/L) ( Figure 5D ) in comparison with HCVcc infected liver slices not treated ( Figure 5B ). The HCQ and GNS396treatment induced an accumulation of LC3Ⅱ protein in HCV infected liver slices treated with 1 µmol/L HCQ or 1 µmol/L GNS396 ( Figure 5D ) in comparison either with not infected liver slices treated ( Figure 5C ) or not ( Figure 5A ), or with HCV infected liver slices without treatment ( Figure 5B ). At day 10, the normalized LC3Ⅱ protein expression increased when liver slices infected ( Figure 5D ) or not ( Figure 5C ) were treated either with GNS396 (1 µmol/L) or HCQ (1 µmol/L). The GNS396 and HCQ effects were tested on the de novo viral production of HCVcc Con1 infected liver slices (Figures 6 and 7) . At day 4 postinfection, HCVcc Con1 infected liver slices were treated for 6 d with different concentrations either of GNS396 or HCQ. From day 1 to day 6 posttreatment, the HCV RNA replication ( Figure 6A and B) and the infectivity ( Figure 7A and B) were inhibited in a dosedependent manner. The addition of RBV with the new drug GNS396 showed no significant difference in the viral inhibition (data not shown).
EC50 analysis of HCV replication with GNS-396 treatment compared to that of validated antiviral drugs
The ability of various concentrations of different antiviral drugs to inhibit HCV replication was measured by de tecting the replication of negative strands HCV RNA ( Figure 6A and C) ( Table 1 ). The calculated EC50 of different antiviral drugs is listed as Table 1 and compared to GNS396. In summary, our model confirms that the antiviral activity of triple therapy was higher than that of the dual therapy by PR as extensively reported in clinical trials [5, 6] . The new quinoline derivative GNS396 has about 10fold lower EC50 than HCQ (0.158 µmol/L as compared to 1.17 µmol/L) ( Figure 6B and D) . No significant cytotoxic effects were observed when evaluated by the lactate dehydrogenase leakage (LDH) assays ( Figure  2A and B) . A 50% cytotoxic concentration (CC50 value) of 25 µmol/L was obtained for GNS396 in the human liver slices culture at day 6 posttreatment. Similar CC50 values were obtained in proliferating Huh751 replicon cells (23 µmol/L).
DISCUSSION
Our study evidenced that: (1) the ex vivo model of human liver slices HCVcc Con1 infection may be efficiently used for the assay of the antiviral potency of a new inhibitor (GNS396 compared to HCQ) which interfered with autophagy; and (2) GNS396 was a potent autophagy inhibitor, acting as "lysosomotropic agent" which was able to inhibit HCV replication in primary human adult HCVcc infected liver slices culture.
The establishment of the ex vivo model (feasibility, rapidity, specificity, potency) was already described in detail in 2012 [41] with comparison between primary human hepatocytes, Huh7.5.1 cell line. The Huh7 cell system has several limitations that includes the inability to study the effects of pharmacologic inhibitors targeting the nonstructural proteins of the most prevalent and problematic viral strains (e.g., genotypes 1a and 1b). Moreover, the study of virus/host cell interactions is limited since the permissive cell lines are transformed and poorly differentiated. Firstly, the human liver slices culture maintains the original threedimensional structure of the liver that allows cell crosstalk: The extracellular matrix and Kupffer cells essential for the normal function of the hepatocytes and the lobular structure. Secondly, the gene expression profiles in liver tissue slices were similar to that of the in vivo gene expression. Thirdly, primary hepatocytes preparations undergo treatment with collagenase (a treatment might have a negative effect on integrity of the proteins repertoire on the cell surface), but not the liver slices. Noteworthy, using esta blished procedures, the tissue slices remained viable for, at least 10 d as it was shown by the secretion of albumin and urea. Moreover, the Huh7 cell infection with primary isolates from patients are not very efficient. The infection of adult human liver slices culture allowed to achieve the robust replication of HCVcc genotype 2a, 1a and 1b genome and to obtain infectivity titers above 105 ffu/mL. In addition, we reported robust and productive infec tion using human primary isolates HCV genotype 1b. Stem cellderived hepatocytes (hESCHeps) displayed equivalence to primary adult hepatocytes. HESCHeps were capable of supporting the full HCV life cycle (JFH1), including the release of infectious virions. Although supportive, hESCHep viral infection levels were not as great as those observed in Huh7 cells. Up to now, the hESCHeps were not infected with primary isolates [55] . Currently, we are establishing a culture of liver slices for 21 d, which allows us to follow the variation of different parameters and in particular, complete inhibition of viral production (data not shown).
Previous studies have reported that autophagy pro teins are required to initiate HCV replication and trans lation [28, 3036] . Some data demonstrated that the suppres sion of LC3 protein lipidation, a necessary step for the formation of autophagosomes could also suppress HCV replication [30] . CQ is a wellknown autophagic inhibitor which is often used as an antimalarial agent. HCQ is a "lysosomotropic" weak base that raises the lysosomal pH quickly [37] . Furthermore, many studies have reported the antiviral effect of CQ on other positive strand RNA viruses, such as polioviruses, coxsackieviruses, dengue viruses, coronaviruses (SARSCoV virus) [2429] , HIV1 [56] .
In our study, we demonstrated the antiviral effect of HCQ and the new quinoline derivative GNS396 on HCVcc replication in a dose dependent manner. Compared to the treatment with HCQ alone, HCQ inhibition was more pronounced in combination with RBV or with other direct antivirals, suggesting a synergistic effect of the combined drugs on HCVcc infection in human liver slices. This result is consistent with a previous study which demonstrated the antiviral effect of CQ in combination with pegIFN in HCV infected Huh7 cell line [33] . Similarly, on Huh7 cells infected with HCVpp (genotype 1a and 3a), it has been shown that CQ reduced by 50% virus infectivity at 50 µmol/L concentration, when the antiviral effect was tested [57] . Recently, ferroquine (FQ), an antimalarial ferrocenic analog of CQ, has been described as a novel inhibitor of HCV. FQ potently inhibited HCV infection of hepatoma cell lines [58] . Compared to these investiga tions, our study using the quinoline derivative GNS396, revealed an inhibition of the virus infectivity up to 93% respectively at day 6 posttreatment with lower drug amounts (EC50 = 0.158 µmol/L). This demonstrates that GNS396 is a stronger antiviral than HCQ (EC50 = 1.17 µmol/L). EC50 is a measure of the effectiveness of the drug in inhibiting the biochemical function. In our study, we evaluated the EC50 of HCV replication at day 6 post treatment. The lower EC50 value indicates the greater potency of inhibiting HCV replication. As shown in Table   1 , the infectivity inhibition, consistent with the inhibition of HCV replication, demonstrated that the new drug evaluated in the human HCV infected liver slices culture model, had a potent antiviral effect compared to the wellknown established antivirals. In combination with the other well established drugs like DAA or inhibitors of other host targets (cyclophilin), quinoline derivatives could be additional therapeutic options for HCV infected patients.
In conclusion, this study demonstrated the relevance of the human HCV infected liver slices culture in preclinical studies of the new antiviral drugs. New host targeted therapies inhibiting autophagy (GNS396, HCQ) have demonstrated significant efficiency and additive activity in inhibiting HCV replication. The ex vivo model of culture of human HCV infected liver slices might allow further evaluation of the efficacy of new antiviral drugs in single or in combined therapy and their potential toxicity in particular for patients "difficult to treat". Moreover, the infection of human liver slices culture with primary viral isolates from patients that we succeed to establish [41] , should allow highlighting the potential of early emergence of drug resistant viral variants during the antiviral treatments. as to the members of the Department of Hepatology in Groupe Hospitalier CochinHôtel Dieu, APHP, Paris, France, for the technical assistance. We are deeply inde bted to Doctor Vladimir A. Morozov and Doctor Matthew Albert for the critical reading of the manuscript.
COMMENTS
Background
Hepatitis C virus (HCV) infection (or spread) is a serious public health challenge counting approximately 170 million people that are chronically infected worldwide. Host antiviral therapy is an additional option for the treatment of HCV infection.
Research frontiers
Interferon-free treatments with new direct acting antivirals are expected to cure more than 90% of HCV-infected patients. But they are not available in all the countries. At the present time, triple therapy combining pegylated interferon-α 2a or b and ribavirin with NS3 protease inhibitors (telaprevir or boceprevir) is going to remain the main treatment for HCV patients. That is why it appears important to continue research in limiting virus replication and the autophagy inhibition could be a new additional pathway because of recent evidences obtained regarding to an increased autophagic response in the liver of chronically HCV infected patients.
Innovations and breakthroughs
This is the first study evaluating a new autophagy inhibitor as antiviral that could inhibit HCV infection in a dose-dependent manner without cytotoxic effect using the relevant ex vivo model of the human liver slices culture.
Applications
This study highlight the relevance of the ex vivo model of the human HCV infected liver slices culture in preclinical studies of the new anti-viral drugs in single or in combined therapy and their potential toxicity in particular for patients "difficult to treat". Moreover, the infection of human liver slices culture with primary viral isolates from patients that the authors succeed to establish, should allow highlighting the potential of early emergence of drug resistant viral variants during the anti-viral treatments.
Terminology
Autophagy is a catabolic process which degrades a cellular own component through the lysosomal machinery. It has been shown that autophagy is activated during virus and bacterial infection and that some viruses can use the autophagy system to facilitate their own replication.
